Product Name:4-(triazol-1-yl)benzoic acid

IUPAC Name:4-(1H-1,2,3-triazol-1-yl)benzoic acid

CAS:216959-87-4
Molecular Formula:C9H7N3O2
Purity:95%+
Catalog Number:CM751086
Molecular Weight:189.17

Packing Unit Available Stock Price($) Quantity
CM751086-1g in stock ţţ
CM751086-5g in stock ĜƏř
CM751086-25g in stock ƩƩŁǎ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:216959-87-4
Molecular Formula:C9H7N3O2
Melting Point:-
Smiles Code:OC(=O)C1=CC=C(C=C1)N1C=CN=N1
Density:
Catalog Number:CM751086
Molecular Weight:189.17
Boiling Point:
MDL No:MFCD20483616
Storage:

Category Infos

Triazoles
Triazole refers to a heterocyclic compound with the molecular formula C2H3N3, which has a five-membered ring consisting of two carbon atoms and three nitrogen atoms. Neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease already affect many people around the world, and these numbers are increasing rapidly. Treatment for these disorders is often aimed at relieving symptoms and has no cure. Research on new molecules is underway, and heterocyclic compounds have important pharmacological implications. Triazoles and tetrazoles are emerging as new molecules in this field.

Column Infos

Bomedemstat
Merck recently announces the initiation of the pivotal Phase 3 randomized MK-3543-006 clinical trial of Bomedemstat for Essential Thrombocythemia (ET). Lysine-specific demethylase 1 (LSD1) is critical for the regulation of hematopoietic stem and progenitor cells. Bomedemstat is an investigational small molecule irreversible inhibitor of LSD1 by suppressing progenitor cells during blood cell maturation. It is generally well tolerated in ET patients and demonstrates significant clinical activity as a monotherapy.
Bomedemstat has been granted Orphan Drug and Fast Track Designation for the treatment of ET and myelofibrosis (MF) by the U.S. FDA.